சிரிய வெள்ளெலி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from சிரிய வெள்ளெலி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In சிரிய வெள்ளெலி Today - Breaking & Trending Today
Isle of Wight's animal friends and the bond their share with owners showcased in virtual pet show (photos) onthewight.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onthewight.com Daily Mail and Mail on Sunday newspapers.
Do rodents make good pets? theportugalnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theportugalnews.com Daily Mail and Mail on Sunday newspapers.
ALG-097111 potently inhibits SARS-CoV-2 replication in Syrian Hamster model in vivo Antiviral drugs have been proven successful as a therapeutic approach to inhibit HCV and HIV viral proteases. With the coronavirus disease 2019 (COVID-19) pandemic causing unprecedented morbidity and mortality, there is an urgent need for effective antivirals to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, scientists across the world have been trying to repurpose existing antivirals designed to treat other viruses. Remdesivir, a nucleotide analog that inhibits the nsp12 polymerase and originally developed for Ebola, was approved to treat SARS (or SARS-CoV-1) as a result of these drug repurposing efforts. Another nsp12 inhibitor, MK-4482/EIDD-2801, is currently being assessed for use in SARS-CoV-2 therapy. ....
Share this article Share this article HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, to the newly formed MolGenie GmbH, a biotech company focusing on drug discovery and development. Anixa and OntoChem were seeking to develop an orally administrable, metabolically stable, non-toxic anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19. The partners had recently completed in vitro antiviral cell-based studies and ....
Share this article Share this article SAN JOSE, Calif., April 5, 2021 /PRNewswire/ Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19. Anixa and OntoChem are seeking to develop an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19. The partners have recently completed POC studies in a Syrian Hamster model of the Covid-19 disease. Two potential compounds were evaluated as well as Remdesivir. Data showed that administration of the drugs to infected hamsters did not cause any noticeable adverse effects, and monitoring of weight and general animal behavior demonstrated comparable efficacy of both Anixa compounds as well as Remdesivir. Viral ....